Last reviewed · How we verify

Corpus Luteum Insufficiency Syndrome — Treatment Landscape & Competitive Intelligence

Corpus Luteum Insufficiency Syndrome (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Corpus Luteum Insufficiency Syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Endometrin progesterone Ferring Progesterone [EPC] Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Progesteron Progesteron Minia University Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ferring · 1 drug in Corpus Luteum Insufficiency Syndrome
  2. Minia University · 1 drug in Corpus Luteum Insufficiency Syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Corpus Luteum Insufficiency Syndrome:

Cite this brief

Drug Landscape (2026). Corpus Luteum Insufficiency Syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/corpus-luteum-insufficiency-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing